Aurobindo Pharma (BOM:524804) E10: ₹64.22 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524804 Aurobindo Pharma Ltd BOM:524804
83 GF Score
Price ₹1,615.15
GF Value ₹1,396.01
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Aurobindo Pharma E10?

Aurobindo Pharma BOM:524804 -1.42% 83 E10 is ₹64.22 as of Jun. 2026. GuruFocus rates BOM:524804 with a GF Score™ of 83/100 and a GF Value™ of ₹1,396.01 (Modestly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Aurobindo Pharma's adjusted earnings per share data for the three months ended in Jun. 2026 was ₹17.860. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹64.22 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Aurobindo Pharma's average E10 Growth Rate was 5.00% per year. During the past 3 years, the average E10 Growth Rate was 6.30% per year. During the past 5 years, the average E10 Growth Rate was 8.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Aurobindo Pharma was 14.20% per year. The lowest was 6.30% per year. And the median was 9.05% per year.

As of today (2026-08-20), Aurobindo Pharma's current stock price is ₹1615.15. Aurobindo Pharma's E10 for the quarter that ended in Jun. 2026 was ₹64.22. Aurobindo Pharma's Shiller PE Ratio of today is 25.15.

During the past 13 years, the highest Shiller PE Ratio of Aurobindo Pharma was 26.84. The lowest was 7.80. And the median was 18.32.


Aurobindo Pharma  (BOM:524804) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Aurobindo Pharma's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=1615.15/64.22
=25.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Aurobindo Pharma was 26.84. The lowest was 7.80. And the median was 18.32.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Aurobindo Pharma E10 Related Terms


Aurobindo Pharma E10 Historical Data

* Premium members only.

The historical data trend for Aurobindo Pharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurobindo Pharma E10 Chart

Aurobindo Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 47.58 52.76 57.11 60.28 63.34

Aurobindo Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.30 62.48 62.85 63.34 64.22

BOM:524804 vs ZTS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurobindo Pharma Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Aurobindo Pharma's Shiller PE Ratio falls into.


BOM:524804
83GF Score
Aurobindo Pharma Ltd BOM:524804
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aurobindo Pharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aurobindo Pharma's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=17.86/167.3573*167.3573
=17.860

Current CPI (Jun. 2026) = 167.3573.

Aurobindo Pharma Quarterly Data

per share eps CPI Adj_EPS
201609 10.400 105.961 16.426
201612 9.880 105.196 15.718
201703 9.100 105.196 14.477
201706 8.850 107.109 13.828
201709 13.330 109.021 20.463
201712 10.160 109.404 15.542
201803 9.020 109.786 13.750
201806 7.780 111.317 11.697
201809 10.440 115.142 15.174
201812 12.150 115.142 17.660
201903 9.990 118.202 14.144
201906 10.850 120.880 15.022
201909 10.920 123.175 14.837
201912 12.040 126.235 15.962
202003 14.750 124.705 19.795
202006 13.320 127.000 17.553
202009 13.780 130.118 17.724
202012 50.310 130.889 64.327
202103 13.590 131.771 17.260
202106 13.140 134.084 16.401
202109 11.890 135.847 14.648
202112 10.320 138.161 12.501
202203 9.830 138.822 11.851
202206 8.880 142.347 10.440
202209 6.990 144.661 8.087
202212 8.380 145.763 9.621
202303 8.640 146.865 9.846
202306 9.740 150.280 10.847
202309 12.830 151.492 14.174
202312 16.040 152.924 17.554
202403 15.560 153.035 17.016
202406 15.690 155.789 16.855
202409 14.000 157.882 14.840
202412 14.560 158.323 15.391
202503 15.560 157.552 16.528
202506 14.200 159.755 14.876
202509 14.610 162.289 15.066
202512 15.670 163.281 16.061
202603 15.860 164.272 16.158
202606 17.860 167.357 17.860

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹64.22 mean?
Aurobindo Pharma (BOM:524804) has a E10 of ₹64.22 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Aurobindo Pharma and its competitors.
Is Aurobindo Pharma's E10 too high?
Aurobindo Pharma's current E10 is ₹64.22. Overall, Aurobindo Pharma has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurobindo Pharma's E10 compare to ZTS?
Aurobindo Pharma's E10 of ₹64.22 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Aurobindo Pharma and its competitors. Aurobindo Pharma's current E10 is ₹64.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurobindo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Aurobindo Pharma (BOM:524804) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,396.01, compared to a current price of ₹1,615.15 — trading 15.7% above its estimated fair value. The current E10 is ₹64.22. Aurobindo Pharma's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Aurobindo Pharma (BOM:524804), the current E10 is ₹64.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aurobindo Pharma (BOM:524804) Overvalued in 2026?

Based on GuruFocus' analysis, Aurobindo Pharma stock appears to be overvalued. The current stock price of ₹1,615.15 is trading 15.7% above its estimated GF Value™ of ₹1,396.01. GuruFocus considers Aurobindo Pharma to be Modestly Overvalued.

Key valuation signals for BOM:524804:

  • E10: ₹64.22
  • GF Value™: ₹1,396.01 vs. price of ₹1,615.15 (15.7% above fair value)
  • GF Score™: 83/100 with 7 warning signs

No single metric tells the full story. See the BOM:524804 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aurobindo Pharma Business Description

Other Exchanges AUROPHARMA:India
Address Plot No. 1, Survey No. 83/1, Galaxy, Floors 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500032
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.
83GF Score

Get the complete analysis for BOM:524804

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,615.15
Price
₹1,396.01
GF Value